Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGEN NASDAQ:LXRX NASDAQ:RGLS NASDAQ:ZBIO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$5.36-2.9%$5.26$1.38▼$7.34$151.34M1.511.27 million shs265,442 shsLXRXLexicon Pharmaceuticals$1.07$0.90$0.28▼$2.18$386.80M1.133.43 million shs1.14 million shsRGLSRegulus Therapeutics$8.16$8.10$0.83▼$8.35$564.92M0.351.02 million shsN/AZBIOZenas BioPharma$15.41-1.9%$11.57$5.83▼$26.25$657.22MN/A148,198 shs164,595 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus-2.90%-10.07%-2.72%+72.35%-11.26%LXRXLexicon Pharmaceuticals0.00%-2.73%+16.82%+57.21%-52.44%RGLSRegulus Therapeutics0.00%0.00%0.00%+3.95%+353.33%ZBIOZenas BioPharma-1.91%-1.60%+50.78%+29.28%+1,540,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGENAgenus4.0754 of 5 stars3.34.00.04.61.31.70.6LXRXLexicon Pharmaceuticals2.3771 of 5 stars3.23.00.00.01.52.50.6RGLSRegulus TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AZBIOZenas BioPharma1.6365 of 5 stars3.50.00.00.02.30.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.67Moderate Buy$16.33204.73% UpsideLXRXLexicon Pharmaceuticals 2.40Hold$3.67242.68% UpsideRGLSRegulus Therapeutics 2.29Hold$8.504.17% UpsideZBIOZenas BioPharma 3.00Buy$36.67137.94% UpsideCurrent Analyst Ratings BreakdownLatest AGEN, ZBIO, RGLS, and LXRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/24/2025LXRXLexicon PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.006/4/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$4.00 ➝ $6.006/4/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$25.005/16/2025ZBIOZenas BioPharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.005/15/2025ZBIOZenas BioPharmaWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$35.005/13/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral5/13/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$3.00 ➝ $4.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$99.52M1.48N/AN/A($13.06) per share-0.41LXRXLexicon Pharmaceuticals$31.21M12.39N/AN/A$0.40 per share2.68RGLSRegulus TherapeuticsN/AN/AN/AN/A$1.17 per shareN/AZBIOZenas BioPharma$5M128.92N/AN/A$7.48 per share2.06Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus-$227.21M-$8.67N/AN/AN/A-196.12%N/A-82.33%8/11/2025 (Estimated)LXRXLexicon Pharmaceuticals-$200.40M-$0.51N/AN/AN/A-568.04%-103.16%-54.95%8/6/2025 (Estimated)RGLSRegulus Therapeutics-$46.36M-$0.73N/AN/AN/AN/A-57.53%-53.26%8/6/2025 (Estimated)ZBIOZenas BioPharma-$156.99M-$3.55N/A∞N/AN/AN/AN/A8/21/2025 (Estimated)Latest AGEN, ZBIO, RGLS, and LXRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/21/2025Q2 2025ZBIOZenas BioPharma-$1.02N/AN/AN/AN/AN/A8/14/2025Q2 2025RGLSRegulus Therapeutics-$0.23N/AN/AN/AN/AN/A8/11/2025Q2 2025AGENAgenus-$0.78N/AN/AN/A$49.71 millionN/A8/6/2025Q2 2025LXRXLexicon Pharmaceuticals-$0.07N/AN/AN/A$4.87 millionN/A5/15/2025Q1 2025ZBIOZenas BioPharma-$1.15-$0.80+$0.35-$0.80$5.00 million$10.00 million5/13/2025Q1 2025LXRXLexicon Pharmaceuticals-$0.10-$0.07+$0.03-$0.07$1.26 million$1.26 million5/12/2025Q1 2025AGENAgenus-$1.61-$1.03+$0.58-$1.03$26.38 million$24.07 million5/8/2025Q1 2025RGLSRegulus Therapeutics-$0.29-$0.15+$0.14-$0.15N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/ALXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/ARGLSRegulus TherapeuticsN/AN/AN/AN/AN/AZBIOZenas BioPharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.110.11LXRXLexicon Pharmaceuticals0.482.222.22RGLSRegulus TherapeuticsN/A16.3116.31ZBIOZenas BioPharmaN/A6.476.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%LXRXLexicon Pharmaceuticals74.70%RGLSRegulus Therapeutics92.38%ZBIOZenas BioPharmaN/AInsider OwnershipCompanyInsider OwnershipAGENAgenus5.50%LXRXLexicon Pharmaceuticals13.90%RGLSRegulus Therapeutics4.35%ZBIOZenas BioPharma16.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44027.42 million25.91 millionOptionableLXRXLexicon Pharmaceuticals140361.49 million311.25 millionOptionableRGLSRegulus Therapeutics3069.23 million66.22 millionOptionableZBIOZenas BioPharmaN/A41.83 million34.93 millionN/AAGEN, ZBIO, RGLS, and LXRX HeadlinesRecent News About These Companies3 Highly Shorted Stocks That Could Be the Next Wall Street Sensations1 hour ago | msn.comZenas BioPharma (NASDAQ:ZBIO) Trading Up 5.3% - Here's WhyJuly 29, 2025 | marketbeat.comZenas Biopharma: A Risky Buy On Upcoming Data Readouts In IgG4, MSJuly 28, 2025 | seekingalpha.comZenas BioPharma (NASDAQ:ZBIO) Shares Down 6.5% - Time to Sell?July 26, 2025 | marketbeat.comZenas BioPharma (NASDAQ:ZBIO) Stock Price Up 11.2% - Here's WhyJuly 14, 2025 | marketbeat.comInnovative Approach and Upcoming Catalysts Drive Buy Rating for Zenas BioPharmaJuly 3, 2025 | tipranks.comZenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)June 20, 2025 | globenewswire.comZBIO DEADLINE MONDAY: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 ...June 17, 2025 | stockhouse.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIOJune 17, 2025 | prnewswire.comInvestors Urged to Contact Levi & Korsinsky for Information Before June 16, 2025 - Zenas BioPharma, Inc. (ZBIO)June 16, 2025 | accessnewswire.comAZBIO INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Zenas BioPharma, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitJune 16, 2025 | globenewswire.comZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineJune 16, 2025 | globenewswire.comJune 16, 2025 Deadline: Join Class Action Lawsuit Against Zenas BioPharma, Inc. (ZBIO) - Contact Levi & KorsinskyJune 16, 2025 | accessnewswire.comAINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines - ZBIOJune 16, 2025 | accessnewswire.comAFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Zenas BioPharmaJune 16, 2025 | businesswire.comSecurities Fraud Class Action Filed Against Zenas BioPharma, Inc. (ZBIO) - Levi & Korsinsky Reminds Investors of June 16, 2025June 16, 2025 | accessnewswire.comAZBIO Investors Have Final Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law FirmJune 16, 2025 | prnewswire.comClass Action Lawsuit Alert: Levi & Korsinsky Reminds Zenas BioPharma, Inc. (ZBIO) Investors of June 16, 2025 DeadlineJune 16, 2025 | accessnewswire.comAFINAL REMINDER ZBIO DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Zenas BioPharma, Inc. Investors to Participate in the Class Action LawsuitJune 16, 2025 | accessnewswire.comAJune 16, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against ZBIOJune 16, 2025 | prnewswire.comZBIO LAWSUIT ALERT: Levi & Korsinsky Notifies Zenas BioPharma, Inc. Investors - Lead Plaintiff Deadline June 16, 2025June 16, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerSoundHound Rises as Short Sellers Exit and AI Demand GrowsBy Thomas Hughes | July 9, 2025View SoundHound Rises as Short Sellers Exit and AI Demand GrowsServiceNow: The 2nd Wave of AI Spending Is HereBy Thomas Hughes | July 25, 2025View ServiceNow: The 2nd Wave of AI Spending Is HereAGEN, ZBIO, RGLS, and LXRX Company DescriptionsAgenus NASDAQ:AGEN$5.36 -0.16 (-2.90%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$5.53 +0.17 (+3.17%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Lexicon Pharmaceuticals NASDAQ:LXRX$1.07 0.00 (0.00%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.08 +0.01 (+0.93%) As of 08/1/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.Regulus Therapeutics NASDAQ:RGLSRegulus Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.Zenas BioPharma NASDAQ:ZBIO$15.41 -0.30 (-1.91%) As of 08/1/2025 04:00 PM EasternZenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
